Vaccines and Infectious Diseases · global
Moving Beyond the Capsular Serotype Chase: High-Throughput Screening Identifies Pneumococcal Protein Vaccine Candidates
The research team narrowed 222 conserved proteins down to a four-antigen combination and observed protection in mouse models of pneumonia and sepsis. This approach could broaden vaccine coverage, but it remains at the preclinical validation stage.
Current pneumococcal vaccines primarily recognize the bacterial capsule. They can effectively prevent disease caused by the serotypes included in their formulations, but it is difficult for them to cover the many diverse and continuously changing strains all at once. By instead targeting proteins shared across different serotypes, vaccines might not need to be continually expanded as capsular types change. The real challenge is how to identify, from the vast bacterial protein library, antigens that both elicit an immune response and genuinely provide protection.
A study published in *Nature Communications* introduced a “Functional Genomic Vaccinology” (FGV) platform that links genome-wide candidate prediction, proteome-scale screening, and immune-function validation into a single workflow. The researchers expressed 222 relatively conserved pneumococcal proteins in vitro. They used them to create a protein microarray and also conjugated the proteins to magnetic beads for mouse immunization experiments.
The first round of screening showed that approximately 40% of the tested proteins elicited significant IgG antibody responses in mice. However, “producing antibodies” is not equivalent to “preventing infection.” The team therefore incorporated findings on how human sera recognized different antigens, narrowing the list to 22, and then examined their serological performance and signals associated with Th17 immune responses. This stepwise elimination design was intended to reduce the potential for misclassification when candidates are selected solely through computer predictions or antibody concentrations.
Finally, the researchers combined four antigens into a multicomponent vaccine and observed protection in mouse models of pneumonia and sepsis. Through epitope mapping, they also identified regions of each protein that may participate in protective immunity. These results provide proof of concept that conserved proteins can be systematically discovered and combined into a vaccine, rather than relying on low-throughput experiments to test them individually by chance.
A potential advantage of protein vaccines is that their targets may span multiple capsular serotypes, thereby reducing gaps caused by the replacement and spread of non-vaccine serotypes. However, this study has not yet demonstrated that the four-antigen formulation can provide broad and durable protection in humans, nor has it established the formulation’s actual coverage of diverse clinical strains. Antibody and Th17 responses in mice also cannot be directly translated into efficacy in humans.
The next stage will still need to confirm the conservation and surface accessibility of the candidate proteins across different circulating strains; determine suitable dosages, adjuvants, manufacturing processes, and safety; and evaluate efficacy in additional animal models and human trials. A patent application for the vaccine formulation described in the study is pending, while the paper is currently an early public version awaiting further editing. Therefore, the more solid achievement at present is the establishment of a scalable antigen-discovery workflow, rather than a broad-spectrum pneumococcal vaccine that is close to market.